1201 related articles for article (PubMed ID: 9024712)
21. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
[TBL] [Abstract][Full Text] [Related]
22. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
23. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L; Baselga J; Eiermann W; Guillem Porta V; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Llombart Cussac A; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez Lopez JJ; Mansutti M; Valagussa P; Bonadonna G;
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8715-21. PubMed ID: 16361558
[TBL] [Abstract][Full Text] [Related]
26. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.
Blajman C; Balbiani L; Block J; Coppola F; Chacon R; Fein L; Bonicatto S; Alvarez A; Schmilovich A; Delgado FM
Cancer; 1999 Mar; 85(5):1091-7. PubMed ID: 10091793
[TBL] [Abstract][Full Text] [Related]
27. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
[TBL] [Abstract][Full Text] [Related]
28. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
Nicholson B; Paul D; Shyr Y; Garrett M; Hande KR; Johnson DH
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-20-S11-23. PubMed ID: 9314294
[TBL] [Abstract][Full Text] [Related]
30. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
[TBL] [Abstract][Full Text] [Related]
31. Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: a phase II study.
Gebbia V; Borsellino N; Testa A; Tirrito M; Varvara F; Cucchiara A; Mauceri G; Girlando A; Ferrara M; Caruso F
Anticancer Res; 1999; 19(4C):3553-7. PubMed ID: 10629652
[TBL] [Abstract][Full Text] [Related]
32. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
33. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.
Hainsworth JD; Jones SE; Mennel RG; Blum JL; Greco FA
J Clin Oncol; 1996 May; 14(5):1611-6. PubMed ID: 8622079
[TBL] [Abstract][Full Text] [Related]
35. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
36. [Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
Chen JA
Zhonghua Zhong Liu Za Zhi; 1993 May; 15(3):202-4. PubMed ID: 8261866
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
[TBL] [Abstract][Full Text] [Related]
38. Treatment of refractory metastatic breast cancer with 5-fluorouracil and levofolinic acid as 48 hours continuous venous infusion.
Gebbia V; Mauceri G; Testa A; Tirrito M; Varvara F; Cucchiara A; Borsellino N; Girlando A; Ferrara M; Caruso F
Anticancer Res; 1999; 19(3B):2289-92. PubMed ID: 10472346
[TBL] [Abstract][Full Text] [Related]
39. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Lin CC; Hsu CH; Huang CY; Cheng AL; Chen J; Vogelzang NJ; Pu YS
Cancer; 2006 Mar; 106(6):1269-75. PubMed ID: 16470604
[TBL] [Abstract][Full Text] [Related]
40. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
